(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
Yemen's Houthis ready to join Iran war if needed, raising new shipping risk- Figure out How to Get a good deal on Your Rooftop Substitution Venture
- No respite for German economy as experts slash forecast over Iran war
- David Duchovny's new thriller has him stripping down at 65. But its chilling premise hits close to home.
- Meet ‘NASA Mike,’ who’s done 105,000 handstands around the world
- Inside the cockpit of RAF tanker during defensive mission against Iranian drones
- NASA's moon mission has begun — here's what's ahead for the Artemis II astronauts
- Step by step instructions to Explore the Close to home Consequence of Cellular breakdown in the lungs
- Geminid meteor shower, one of the year's most reliable, peaks this weekend
